Abstract 151P
Background
Gastric cancer (GC) is the fourth leading cause of cancer-related deaths in Taiwan. Even with significant strides that have been made in GC early detection and management in Taiwan in recent years, patients with GC (including gastro-esophageal junction cancer, GEJC) that present with unresectable advanced metastatic disease (UAM) remain at risk for poor survival outcomes.
Methods
This was a retrospective ‘real world’ observational study using the linked Taiwan National Health Insurance Research Database, which contains health claims data on almost the entire Taiwan population, and the Taiwan National Cancer Registry. Patients having at least one hospital record with a primary ICD-9 or ICD-10 code of GC/GEJC were selected from Jan 1st, 2013 through Dec 31st, 2018. The first date of GC/GEJC diagnosis was defined as the index date. Patients were followed for a minimum ± 30 days from the index date and were stratified by staging, clinical presentation [i.e. resectable vs. unresectable advanced metastatic (UAM)]. Key characteristics such as demographics, clinical parameters, medication utilization, health care resource utilization, costs incurred, and survival were tracked for the overall population and both cohorts.
Results
A total of 3736 UAM GC patients were identified with a mean age of 68.0 (sd=15.2) years, with most patients being male (n=2248, 60.2%). The majority of UAM GC patients were Stage 4 (n=2270, 60.8%) and most patients were identified as having adenocarcinoma (n=2847, 76.2%). Nearly half the patients received 1st line (1L) therapy (n=1846, 49.4%) with the most common 1L therapies being Capecitabine + Oxaliplatin (n=604, 32.7% of 1L), S-1 (n=280, 15.2% of 1L) and Capecitabine monotherapy (n=209, 11.3% of 1L). Only 38.2% (n=1428) of patients survived 1 year with the annualized post-index GC-related costs being New Taiwan (NT) $ 396,590 (sd = NT$ 412,523).
Conclusions
The most common 1L chemotherapeutic treatments for UAM GC patients were Capecitabine + Oxaliplatin, S-1 and Capecitabine. In Taiwan, UAM GC patients appear to have poor survival and incur high GC-related costs, which suggests the need for new treatment options.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol-Myers Squibb Pharmaceuticals Corp.
Funding
Bristol-Myers Squibb Pharmaceuticals Corp.
Disclosure
C.J. Chang, Y. Tsai, H.S. Friedman, P. Navaratnam: Research grant/Funding (self): Bristol-Myers Squibb. J. Gricar, H. Xiao: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb.
Resources from the same session
143P - Lymph nodes metastasis is the most important factor associated with pattern of recurrence following curative resection of gastric adenocarcinoma
Presenter: Fu-Hai Wang
Session: e-Poster Display Session
144P - Clinical implication of DNA damage response gene in patients with stage II or III gastric cancer
Presenter: In Gyu Hwang
Session: e-Poster Display Session
145P - A nomogram for predicting the benefit of adjuvant chemotherapy after resection in patients with Borrmann type IV gastric cancer
Presenter: Qing-Zhu Qiu
Session: e-Poster Display Session
146P - Red cell distribution width and mean corpuscular volume ratio as a promising new marker for chemotherapy effects in remnant gastric cancer: An analysis of a multi-institutional database
Presenter: Kai-Xiang Xu
Session: e-Poster Display Session
147P - Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?
Presenter: Hayato Watanabe
Session: e-Poster Display Session
148P - MCV-the ideal answer to predict the prognosis of remnant gastric cancer: An analysis from a multi-institutional database
Presenter: Kai Weng
Session: e-Poster Display Session
149P - Molecular and clinical characteristics of patients with resectable gastric cancer
Presenter: Zhi Zheng
Session: e-Poster Display Session
150P - Real-world assessment of the treatment patterns associated with unresectable advanced and metastatic gastric cancer in China
Presenter: Xiao Sun
Session: e-Poster Display Session
152P - ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Presenter: Koji Kase
Session: e-Poster Display Session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session